$DRTSW News
Last published 1w ago
- 1w agoDRTSDRTSWAlpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock ExchangeGlobeNewswireFunds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdings TA-125 tracks the 125 largest and most prominent companies on the TASE JERUSALEM, Oct. 29, 2026 (GLOBE NEWSWIRE)
- 2w agoDRTSDRTSWAlpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in KoreaGlobeNewswire- MOU relates to a potential clinical trial in South Korea, Alpha DaRT’s first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology - - In Korea, only about one in
- 3w agoDRTSDRTSWAlpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual MeetingGlobeNewswire- FDA approves IDE supplement expanding REGAIN from 10 to 20 patients, with additional study endpoints and interim analysis - - Abstract authored by REGAIN study principal investigator Dr. Joshua Palmer of The Ohio
- 2mo agoDRTSDRTSWAlpha Tau to Participate in September Investor ConferencesGlobeNewswireJERUSALEM, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®,
- 2mo agoDRTSDRTSWAlpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple ExpansionsGlobeNewswire- IMPACT, a multicenter pilot study of Alpha DaRT® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 patients to a total
- 3mo agoDRTSDRTSWAlpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to
- 3mo agoDRTSDRTSWAlpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)GlobeNewswireJERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®,
- 3mo agoDRTSDRTSWAlpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for SuccessGlobeNewswire- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in
- 3mo agoDRTSDRTSWAlpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer CenterGlobeNewswire- The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which the Banner MD
- 4mo agoDRTSDRTSWAlpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in IsraelGlobeNewswire- First glioblastoma patient ever treated with Alpha DaRT® outside of the United States, and the first in Israel - performed at Hadassah University Medical Center in Jerusalem, one of the world’s premier academic
- 5mo agoDRTSDRTSWAlpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease ControlGlobeNewswire- Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for the remaining seven patients in the
- 5mo agoDRTSDRTSWAlpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer PatientsGlobeNewswire- Joint partnership leverages Alpha Tau's highly potent, localized alpha-radiation technology and Tolmar's commercial leadership to transform the U.S. uro-oncology landscape - Collaboration elevates prostate cancer as
- 5mo agoDRTSDRTSWAlpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual MeetingGlobeNewswire- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of three prospective Phase
- 5mo agoDRTSDRTSWAlpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of patient enrollment
- 5mo agoDRTSDRTSWAlpha Tau to Participate in May Investor ConferencesGlobeNewswireJERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today
- 6mo agoDRTSDRTSWAlpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ETGlobeNewswire- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since treatment - - One
- 6mo agoDRTSDRTSWAlpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent GlioblastomaGlobeNewswireJERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau", or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today
- 6mo agoDRTSDRTSWAlpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell CarcinomaGlobeNewswire- First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA modular application
- 6mo agoDRTSDRTSWAlpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas InstituteGlobeNewswireFirst patient ever treated with Alpha DaRT for pancreatic cancer in Italy, under a clinical study conducted at the world-renowned Pancreas Institute of the University of VeronaThe study is the first Alpha DaRT pancreatic
- 6mo agoDRTSDRTSWAlpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with PembrolizumabGlobeNewswire- Abstract from trial evaluating Alpha DaRT® in combination with pembrolizumab in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma selected for podium presentation - - The
- 6mo agoDRTSDRTSWAlpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026GlobeNewswire- 100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-human trials of Alpha DaRT® in pancreatic adenocarcinoma - - Favorable safety profile observed, with only 8
- 6mo agoDRTSDRTSWAlpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer StudiesGlobeNewswire- Abstract accepted at the American Society of Clinical Oncology (ASCO) Annual Meeting - the world's largest and most prestigious medical oncology conference - - Pooled analysis combines safety and efficacy data from 58
- 6mo agoDRTSDRTSWAlpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)GlobeNewswire- IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX - - IDE supplement also expands total trial size from 30 to 40 patients - -
- 6mo agoDRTSDRTSWAlpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical TrialGlobeNewswireACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics combined with capecitabine for inoperable LAPC patients who have completed first-line mFOLFIRINOX, a population
- 7mo agoDRTSDRTSWAlpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026GlobeNewswireJERUSALEM, March 31, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that an abstract
- 8mo agoDRTSDRTSWAlpha Tau to Present at Sidoti March Virtual Small Cap ConferenceGlobeNewswireJERUSALEM, March 16, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that CFO
- 8mo agoDRTSDRTSWAlpha Tau Announces Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain
- 8mo agoDRTSDRTSWAlpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck CancerGlobeNewswire- Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength
- 9mo agoDRTSDRTSWAlpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones AheadGlobeNewswire- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal
- 10mo agoDRTSDRTSWAlpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)GlobeNewswire- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from the
- 10mo agoDRTSDRTSWAlpha Tau to Present at the J.P. Morgan 2026 Healthcare ConferenceGlobeNewswireJERUSALEM, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today
- 11mo agoDRTSDRTSWAlpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State UniversityGlobeNewswire- First patient in the world treated with Alpha DaRT® in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an
- 11mo agoDRTSDRTSWAlpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI SymposiumGlobeNewswireJERUSALEM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®,
- 11mo agoDRTSDRTSWAlpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate CancerGlobeNewswireJERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that the FDA has approved an
- 11mo agoDRTSDRTSWAlpha Tau to Participate in December Investor ConferencesGlobeNewswireJERUSALEM, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today
- 11mo agoDRTSDRTSWAlpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire- Alpha DaRT pancreatic cancer patient treatments underway in U.S. multi-center pilot study - - Newly received radioactive material license for New Hampshire facility positions the Company for continued advancement
- 1y agoDRTSDRTSWAlpha Tau to Participate at Jefferies Global Healthcare Conference in LondonGlobeNewswireJERUSALEM, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today
- 1y agoDRTSDRTSWAlpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial ReadinessGlobeNewswire- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT®, the innovative alpha-radiation cancer therapy designed for potent and conformal tumor
- 1y agoDRTSDRTSWAlpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical TrialGlobeNewswire– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – – Study explores Alpha DaRT® combined with chemotherapy in patients with newly
- 1y agoDRTSDRTSWAlpha Tau to Participate in Five September Investor ConferencesGlobeNewswireJERUSALEM, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today
- 1y agoDRTSDRTSWAlpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer - - Multiple U.S. clinical trials, including
- 1y agoDRTSDRTSWAlpha Tau to Present at Jefferies Global Healthcare ConferenceGlobeNewswireJERUSALEM, May 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today
- 1y agoDRTSDRTSWAlpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire- Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive overall
- 1y agoDRTSDRTSWAlpha Tau Announces Appointment of Nadav Kidron to its Board of DirectorsGlobeNewswireJERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®,
- 1y agoDRTSDRTSWAlpha Tau to Participate in May Investor ConferencesGlobeNewswireJERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today
- 1y agoDRTSDRTSWORMPAlpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed PharmaceuticalsGlobeNewswireJERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®,
- 1y agoDRTSDRTSWAlpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent GlioblastomaGlobeNewswireJERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an
- 1y agoDRTSDRTSWAlpha Tau Announces Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswire- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -
- 1y agoDRTSDRTSWAlpha Tau to Participate in March Investor ConferencesGlobeNewswireJERUSALEM, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today
- 1y agoDRTSDRTSWAlpha Tau Receives Medical Device Single Audit Program (MDSAP) CertificationGlobeNewswireJERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today